Rosuvastatin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PHARMAC (New Zealand) recommended or restricted rosuvastatin, while AWMSG (Wales), CONITEC (Brazil) and SMC (Scotland) did not recommend it.
CIPM (Spain) has been harder on rosuvastatin than on its own caseload: it refused 7 of 8 decisive submissions here (88%), against a base rate of 63% across everything it has assessed.
The file has been open for more than a decade: 22.6 years separate the first record, 9 May 2003 at SMC (Scotland), from the most recent, 29 Dec 2025 at CONITEC (Brazil).
CIPM (Spain) changed its position: not recommended on 12 Nov 2020, recommended by 19 Nov 2025, after a resubmission.
No assessment is on file from PBAC (Australia), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Against its own class, rosuvastatin is an outlier: 20% of its decisive outcomes were positive, where molecules sharing ATC class C10A average 68%.
SMC (Scotland) was first to assess rosuvastatin, on 9 May 2003; CONITEC (Brazil) did not open a file until 29 Dec 2025 — an unusually long tail of 22.6 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 12 years in total.
4 of the 6 agencies here assessed rosuvastatin more than once, HAS (France) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for rosuvastatin.
The full ledger for rosuvastatin reads 12 not recommended, 8 other and 3 recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 19 Nov 2025 | Indicación terapéutica autorizada: Fenzil está indicado como tratamiento complementario a la dieta y otros tratamientos … | financed by the SNS · art. 92 e | source |
| PHARMAC (New Zealand) | 8 May 2019 | Hypercholesterolemia / cardiovascular risk (3rd-line statin treatment) | PTAC advice: No Formal Recommendation · decision reached | source |
| HAS (France) | 20 Feb 2019 | Indication extension | SMR insufficient · ASMR V | source |
| AWMSG (Wales) | 17 Jan 2012 | Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular e… | not recommended (full) | source |
| SMC (Scotland) | 10 Oct 2011 | For the prevention of major cardiovascular events in patients estimated to have a high risk for a first cardiovascular event. | not recommended | source |
18 further decisions for rosuvastatin, across 5 agencies, are not shown here. They include the most recent record on file, 29 Dec 2025 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- evolocumab — same ATC class C10A — Lipid modifying agents
- alirocumab — same ATC class C10A — Lipid modifying agents
- inclisiran — same ATC class C10A — Lipid modifying agents
- evinacumab — same ATC class C10A — Lipid modifying agents
- ezetimibe — same ATC class C10A — Lipid modifying agents
- fenofibrate — same ATC class C10A — Lipid modifying agents
Coverage: 23 decisions for rosuvastatin from 6 agencies, 2003 to 2025. Data to 7 Sep 2026. ATC class C10A — Lipid modifying agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.